- Home
- IBIO vs RSSS Comparison
IBIO vs RSSS Comparison
Compare IBIO & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | RSSS |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 76.6M |
| IPO Year | 2009 | 2008 |
Fundamental Metrics
Financial Performance| Metric | IBIO | RSSS |
|---|---|---|
| Price | $1.73 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.75 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 989.2K | 54.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 73.08 | ★ 130.77 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $28,793,922.00 |
| Revenue This Year | N/A | $1.81 |
| Revenue Next Year | N/A | $5.73 |
| P/E Ratio | ★ N/A | $33.00 |
| Revenue Growth | N/A | ★ 2.77 |
| 52 Week Low | $0.56 | $2.00 |
| 52 Week High | $3.82 | $4.12 |
Technical Indicators
Market Signals| Indicator | IBIO | RSSS |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 51.95 |
| Support Level | $1.70 | $2.19 |
| Resistance Level | $1.80 | $2.37 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 38.89 | 57.69 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.